Table 3.

Demographic and clinical characteristics of patients who started treatment with dose reduction

Demographic characteristics
Age, n (%)	(n = 68)
< 65 years		33 (48.5%)
65–79 years		14 (20.6%)
≥ 70 years		21 (30.9%)
Sex, n (%)	(n = 68)
Males		41 (60.3%)
Females		27 (39.7%)
Clinical characteristics
Weight loss > 10%, n (%)	(n = 66)	18 (27.3%)
ECOG PS, n (%)	(n = 62)
0–1		46 (74.2%)
2-Mar		16 (25.8%)
Karnofsky PS, n (%)	(n = 23)
< 70		–
70–80		13 (56.5%)
90–100		10 (43.5%)
Common comorbidities, n (%)	(n = 68)
Hypertension		15 (22.1%)
Diabetes		8 (11.8%)
Dyslipemia		4 (5.9%)
Hepatobiliary stent, n (%)	(n = 68)	10 (14.7%)
Platelet count, median (IR)	(n = 57)	252.0 (172.0, 339.0)
Bilirubin (mg/dL), median (IR)	(n = 58)	0.70 (0.51, 1.10)
NLR, n (%)	(n = 55)
> 3		29 (52.7%)
≤ 3		26 (47.3%)
CA 19.9, n (%)	(n = 62)
> 35		52 (83.9%)
≤ 35		10 (16.1%)
Number of metastatic sites, n (%)	(n = 68)
1–3		67 (98.5%)
> 3		1 (1.5%)
Concommitant treatment, n (%)	(n = 68)
Analgesics		22 (32.4%)
Corticosteroids		9 (13.2%)

IR Interquartile range (percentile 25, percentile 75)

^anumber of evaluable patients (no-missing)